Daily treatment with SC0023 yielded treatment efficacy 53.5% ± 19.2% relative to baseline in 24-hour daily cough rate and 19.5% ± 6.2% placebo effect Cough rate reduction was observed from the first ...
On Monday, Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Between baseline and day 21, there was a –67% change in ...
Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn., Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (TRVI) (Nasdaq: TRVI), a clinical-stage biopharmaceutical company ...
Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline Haduvio showed similar efficacy in ...
Camlipixant showed significant efficacy in patients with higher baseline cough frequency, despite not meeting the primary endpoint in the overall population. The trial demonstrated camlipixant's ...
Shares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER study evaluating its investigational therapy Haduvio as a potential treatment ...
Serious adverse events (all non-fatal) were reported for four patients (10.0%) in the placebo group and for two patients (1.6%) treated with nalbuphine ER. About Idiopathic Pulmonary Fibrosis (IPF) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results